The marker in question is called DOPA decarboxylase (DCC). In the current study, DCC was found to be elevated in individuals with Parkinson’s disease as well as in people with other diseases that result in dopamine deficiency in the brain. However, the marker was normal in other brain diseases such as Alzheimer’s disease. The researchers even noticed that DCC was elevated in individuals with Parkinson’s many years before they developed any symptoms.
EU adviser says Illumina merger was not problematic
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hi, it’s Meghana. Today,
March 22, 2024